A decline in international revenue had a negative impact on Milestone Scientific’s second-quarter financials. The company reported revenues of $2.5 million for the second quarter
Cancer patients may benefit from sessions with trained music therapists or from listening to music. A new Cochrane systematic review shows using music can reduce
A syringe modification, which promises reduced pain for dental injections, has won a major innovation award for its creators. The syringe cartridge works by reducing
A recent study published in Psychotherapy and Psychosomatics examines alternatives to general anesthesia for patients who have dental anxiety. Cognitive behavioral treatment (CBT) was better
Pierrel Research USA, a subsidiary of Pierrel SpA, will officially launch its new Orabloc articaine product in the U.S. at the California Dental Association (CDA)
The root cause of local anesthetic-related neurosensory disturbances (NSDs) in dentistry has been unclear. But now a group of Danish researchers say it is neurotoxicity
Milestone Scientific reported revenues of $9.75 million for 2010 (end-December 31, 2010), up 14% from $8.55 million in the previous year. Sales in the U.S.
The U.S. Food and Drug Administration (FDA) has approved vandetanib to treat adult patients with late-stage medullary thyroid cancer who are ineligible for surgery and
While only 1.5% of dentists who contribute to research in dental anesthesiology are trained dental anesthesiologists (DAs), they are responsible for 10% of the publications,
Buccal infiltration is more effective than lingual infiltration in obtaining anesthesia of the first mandibular molar and premolar teeth, according to researchers from the Newcastle
Following its announcement last week that it had sold its only commercial product to Septodont, Novalar is on the verge of shutting down completely, according
Septodont has acquired the OraVerse product line from Novalar Pharmaceuticals, the companies announced today. OraVerse is the first local anesthesia reversal agent to gain U.S.
